联合用药治疗HBeAg阳性慢性乙型肝炎应答不佳患者疗效及安全性

发布时间：2018-02-08 21:41

本文关键词： 慢性乙型肝炎 HBeAg阳性应答不佳阿德福韦酯聚乙二醇干扰素-a　出处：《中华医院感染学杂志》2015年06期 　论文类型：期刊论文

【摘要】：目的探讨阿德福韦酯联合聚乙二醇干扰素-2a治疗HBeAg阳性慢性乙型肝炎应答不佳者疗效及安全性,为临床诊治提供参考依据。方法选取80例HBeAg阳性慢性乙型肝炎患者,给予聚乙二醇干扰素-2α皮下注射治疗,治疗24周时根据HBV-DNA水平分为有应答反应组24例、应答不佳组56例,再将应答不佳组随机分为A、B组,每组各28例,A组加用阿德福韦酯治疗,B组仍原方案治疗,观察各组治疗前、治疗24、48周时相关指标变化及药物不良反应发生。结果治疗24周应答不佳组HBV-DNA、HBeAg高于有应答反应组(P0.05);48周时A、B组、有应答反应组HBV-DNA转阴率分别为67.76%、39.29%、100.00%,HBeAg血清转阴率A、B组、有应答反应组分别为50.00%、21.43%、50.00%,A、B组及有应答反应组不良反应发生率分别为46.43%、32.14%、33.33%,各组比较差异无统计学意义。结论 HBeAg阳性慢性乙型肝炎患者聚乙二醇干扰素-2a治疗应答不佳时可联合使用阿德福韦酯,能明显提高HBV-DNA与HBeAg血清转阴率。
[Abstract]:Objective to investigate the efficacy and safety of adefovir ester combined with polyethylene glycol interferon 2a in the treatment of HBeAg positive chronic hepatitis B patients, and to provide reference for clinical diagnosis and treatment. Methods 80 patients with HBeAg positive chronic hepatitis B were selected. After subcutaneous injection of pegyleneglycol interferon 2 伪, 24 patients were divided into two groups according to the level of HBV-DNA: response group (n = 24) and poor response group (n = 56). 28 cases in each group were treated with adefovir dipivoxil. Results the HBeAg of HBV-DNA in the group with poor response at 24 weeks was higher than that in the group with response (P 0.05) at 48 weeks after treatment, and the negative rate of HBV-DNA in the group with response was 67.767.76 / 39.29g / 100.000.The negative rate of HBV-DNA in group A was higher than that in group B at 48 weeks after treatment, and the negative rate of HBV-DNA in group B was higher than that in group B, and the negative rate of HBeAg in group B was 67.767.76% 39.29%, respectively. The incidence of adverse reactions in group B and group B were 46.43 and 32.14 and 33.33, respectively. There was no significant difference between the two groups. Conclusion there is no significant difference between the two groups. Conclusion there is no significant difference in the response of HBeAg positive patients with chronic hepatitis B by pegyleneglycol interferon 2a. Conclusion\\\; Can be used in combination with adefovir ester, The serum negative rate of HBV-DNA and HBeAg was significantly increased.
【作者单位】：新乡医学院第一附属医院感染一科;新乡医学院第一附属医院妇产二科;
【基金】：河南省卫生厅重点基金资助项目(201303106)
【分类号】：R512.62

【参考文献】